GABA A receptor agonist-Pipeline Insight, 2021 | Analytical Research Cognizance

GABA A receptor agonist-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667925
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “GABA A receptor agonist - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in GABA A receptor agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Global coverage
GABA A receptor agonist Understanding
GABA A receptor agonist: Overview
Type-A γ-aminobutyric acid receptors (GABAARs) are the principal mediators of rapid inhibitory synaptic transmission in the human brain. A decline in GABAAR signalling triggers hyperactive neurological disorders such as insomnia, anxiety and epilepsy. GABAARs are the targets of a wide range of drugs including benzodiazepines, used in the treatment of epilepsy, insomnia, anxiety and panic disorder, and the intravenous general anaesthetics propofol and etomidate. GABAARs also mediate alcohol inebriation and are targets for endogenous modulators such as neurosteroids.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence GABA A receptor agonist R&D. The therapies under development are focused on novel approaches for GABA A receptor agonist.
GABA A receptor agonist Emerging Drugs Chapters
This segment of the GABA A receptor agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
GABA A receptor agonist Emerging Drugs
Ganaxolone: Marinus Pharmaceuticals
Ganaxolone is a GABAA receptor modulator that acts by regulating brain activity. This process can include inhibiting the abnormal electrical discharges that cause seizures and status epilepticus or restoring balance in disrupted neuronal activity in other neurologic and psychiatric disorders. GABA is the chief inhibitory neurotransmitter in the brain. Ganaxolone binds to one of the receptor subtypes, the GABAA receptor. When this receptor is activated, it increases the movement of chloride ions through a pore on the cell surface. This action changes the positive and negative charges inside and outside the cell, which inhibits the firing of the neuron. Ganaxolone is an analogue of the naturally occurring neurosteroid, allopregnanolone. Neurosteroids do not possess the metabolic effects of other steroids; rather, they regulate the balance of excitatory and inhibitory brain activity. Ganaxolone has been designed with an added methyl group that prevents back-conversion to an active steroid intended to better maintain its specific neuromodulatory activity.
Padsevonil: UCB Biopharma
Padsevonil is a dual-acting antiepileptic drug that has a mechanism of action designed specifically to interact with pre- and post-synaptic targets. Presynaptically, it binds with high affinity to the three isoforms of synaptic vesicle protein 2: SV2A, SV2B and SV2C. Postsynaptically, it binds with moderate affinity to the benzodiazepine recognition site on the GABAA receptor, where it acts as a partial agonist. Previous results of a Phase II proof-of-concept study demonstrated that treatment with padsevonil may be associated with a clinically meaningful reduction in focal seizure frequency and suggested an acceptable tolerability/safety profile. It is currently in Phase II/III stage of development (NCT03370120).
Further product details are provided in the report……..

GABA A receptor agonist: Therapeutic Assessment
This segment of the report provides insights about the different GABA A receptor agonist drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on GABA A receptor agonist
There are approx. 10+ key companies which are developing the GABA A receptor agonist. The companies which have their GABA A receptor agonist drug candidates in the most advanced stage, i.e. Phase III include, Marinus Pharmaceuticals.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III and
Mid-stage products (Phase II and
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
GABA A receptor agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Infusion
Intradermal
Intramuscular
Intranasal
Intravaginal
Oral
Parenteral
Subcutaneous
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

GABA A receptor agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses GABA A receptor agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging GABA A receptor agonist drugs.

GABA A receptor agonist Report Insights
GABA A receptor agonist Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
GABA A receptor agonist Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Scenario and Emerging Therapies:
How many companies are developing GABA A receptor agonist drugs?
How many GABA A receptor agonist drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for GABA A receptor agonist?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the GABA A receptor agonist therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for GABA A receptor agonist and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Marinus Pharmaceuticals
UCB Biopharma
Confluence Pharmaceuticals
Cerevel Therapeutics
Sichuan Haisco Pharmaceutical
Ovid Therapeutics

Key Products
Ganaxolone
Padsevonil
Acamprosate
Darigabat
Ciprofol
OV101

Introduction
Executive Summary
GABA A receptor agonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
GABA A receptor agonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
GABA A receptor agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
GABA A receptor agonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Ganaxolone: Marinus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Padsevonil: UCB Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Darigabat: Cerevel Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
GABA A receptor agonist Key Companies
GABA A receptor agonist Key Products
GABA A receptor agonist- Unmet Needs
GABA A receptor agonist- Market Drivers and Barriers
GABA A receptor agonist- Future Perspectives and Conclusion
GABA A receptor agonist Analyst Views
GABA A receptor agonist Key Companies
Appendix

Table 1 Total Products for GABA A receptor agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for GABA A receptor agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products